Document is current
Any future updates will be listed below
-
Authors
Iyoda, Shinju
Yoshida, Kenichi https://orcid.org/0000-0003-4612-2778
Shoji, Kota
Ito, Nana
Tanaka, Miu
Nannya, Yasuhito
Yamato, Genki https://orcid.org/0000-0003-4000-0753
Tsujimoto, Shinichi https://orcid.org/0000-0001-5738-4138
Shiba, Norio
Hayashi, Yasuhide
Shiozawa, Yusuke
Shiraishi, Yuichi
Chiba, Kenichi
Okada, Ai
Tanaka, Hiroko
Miyano, Satoru https://orcid.org/0000-0002-1753-6616
Koga, Yuhki
Goto, Hiroaki
Moritake, Hiroshi https://orcid.org/0000-0001-5471-7646
Terui, Kiminori https://orcid.org/0000-0003-1294-8635
Ito, Etsuro https://orcid.org/0000-0002-0168-2475
Kiyokawa, Nobutaka https://orcid.org/0000-0001-9310-2126
Tomizawa, Daisuke https://orcid.org/0000-0003-1520-7007
Taga, Takashi https://orcid.org/0000-0003-0525-4766
Tawa, Akio
Takita, Junko https://orcid.org/0000-0002-2452-6520
Nishikori, Momoko
Adachi, Souichi
Ogawa, Seishi
Matsuo, Hidemasa https://orcid.org/0000-0002-7578-006X
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (JP19K16832, JP22K08475, JP23K07264)
Japan Agency for Medical Research and Development (Practical Research for Innovative Cancer Control, Project for Development of Innovative Research on Cancer Therapeutics, Project for Cancer Research and Therapeutic Evolution)
- License Information
-
More Information
Article History
Received: 19 March 2024
Revised: 31 March 2024
Accepted: 3 April 2024
First Online: 18 April 2024
Competing interests
: SO: Leadership position/advisory role for Eisai, Chordia Therapeutics. Stockholder in: Asahi Genomics. Grant/Research funding from Chordia Therapeutics, Otsuka Pharmaceutical, Eisai. The remaining authors declare no competing financial interests.
